Patent application number | Description | Published |
20100316595 | Methods for treating renal cell carcinoma - Methods for treating renal cell carcinoma using low doses of IL-2 are disclosed. In particular, the invention relates to methods of treating metastatic renal cell carcinoma in patients who are renally impaired and/or intolerant of high dose IL-2 therapy. The therapeutic regimen described herein significantly inhibits tumor growth with reduced toxicity and adverse side effects compared to high dose IL-2 therapy. | 12-16-2010 |
20110263685 | Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy - The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment. | 10-27-2011 |
20120087915 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 04-12-2012 |
20120100138 | THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 04-26-2012 |
20120183535 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 07-19-2012 |
20130195852 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 08-01-2013 |
20130202611 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 08-08-2013 |
20130273030 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 10-17-2013 |
20130310402 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 11-21-2013 |
20140079690 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS - Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors. | 03-20-2014 |
20140194446 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 07-10-2014 |
20140303191 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor. | 10-09-2014 |
20150031710 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 01-29-2015 |
20150031711 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 01-29-2015 |
20150044217 | METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER - Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib. | 02-12-2015 |